共 28 条
[1]
Kopetz S., Chang G.J., Overman M.J., Et al., Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy, J Clin Oncol, 27, pp. 3677-3683, (2009)
[2]
Hurwitz H., Fehrenbacher L., Novotny W., Et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, pp. 2335-2342, (2004)
[3]
Loupakis F., Cremolini C., Masi G., FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial, J Clin Oncol, 30, (2012)
[4]
Cunningham D., Lang I., Lorusso V., Et al., Bevacizumab (bev) in combination with capecitabine (cape) for the firstline treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX), J Clin Oncol, 30, (2012)
[5]
Bennouna J., Sastre J., Arnold D., Et al., Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial, Lancet Oncol, 14, pp. 29-37, (2013)
[6]
Van C.E., Tabernero J., Lakomy R., Et al., Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen, J Clin Oncol, 30, pp. 3499-3506, (2012)
[7]
Van C.E., Kohne C.H., Hitre E., Et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 360, pp. 1408-1417, (2009)
[8]
Douillard J.Y., Siena S., Cassidy J., Et al., Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study, J Clin Oncol, 28, pp. 4697-4705, (2010)
[9]
Sawada K., Radjabi A.R., Shinomiya N., Et al., C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion, Cancer Res, 67, pp. 1670-1679, (2007)
[10]
Shattuck D.L., Miller J.K., Carraway III K.L., Et al., Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells, Cancer Res, 68, pp. 1471-1477, (2008)